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Abstract
Background
Metastasis is the main cause of cancer patient deaths and remains a poorly characterized
process. It is still unclear when in tumor progression the ability to metastasize arises and
whether this ability is inherent to the primary tumor or is acquired well after primary tumor
formation. Next-generation sequencing and analytical methods to define clonal heteroge-
neity provide a means for identifying genetic events and the temporal relationships between
these events in the primary and metastatic tumors within an individual.
Methods and Findings
We performed DNA whole genome and mRNA sequencing on two primary tumors, each
with either four or five distinct tissue site-specific metastases, from two individuals with tri-
ple-negative/basal-like breast cancers. As evidenced by their case histories, each patient
had an aggressive disease course with abbreviated survival. In each patient, the overall
gene expression signatures, DNA copy number patterns, and somatic mutation patterns
were highly similar across each primary tumor and its associated metastases. Almost
every mutation found in the primary was found in a metastasis (for the two patients, 52/54
and 75/75). Many of these mutations were found in every tumor (11/54 and 65/75, respec-
tively). In addition, each metastasis had fewer metastatic-specific events and shared at
least 50% of its somatic mutation repertoire with the primary tumor, and all samples from
each patient grouped together by gene expression clustering analysis. TP53 was the only
mutated gene in common between both patients and was present in every tumor in this
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study. Strikingly, each metastasis resulted from multiclonal seeding instead of from a single
cell of origin, and few of the new mutations, present only in the metastases, were expressed
in mRNAs. Because of the clinical differences between these two patients and the small
sample size of our study, the generalizability of these findings will need to be further exam-
ined in larger cohorts of patients.
Conclusions
Our findings suggest that multiclonal seeding may be common amongst basal-like breast
cancers. In these two patients, mutations and DNA copy number changes in the primary
tumors appear to have had a biologic impact on metastatic potential, whereas mutations
arising in the metastases were much more likely to be passengers.
Author Summary
Background
• In the United States, 40,000 women die of breast cancer each year, thus making it the
second leading cause of cancer-related deaths in women.
• Breast cancer mortality is caused by metastasis, the spread of the cancer beyond the
breast to distant tissue sites, including the lungs, brain, and liver.
• Triple-negative breast cancer, defined by lack of expression of the estrogen and proges-
terone receptors and absent amplification of the HER2 gene, and the basal-likemolecu-
lar subtype defined by RNA gene expression have earlier occurrences of metastasis,
worsened survival, and fewer therapeutic options compared to other breast cancer
subtypes.
Why Was This Study Done?
• This study was done to gain an understanding of the underlying genetics leading to
breast cancer metastasis and when these changes occur temporally.
• Previous reports of the evolution of breast cancer metastasis have reported one to two
matched metastasis sites and did not focus on triple-negative breast cancer, the subtype
with the greatest clinical need.
What Did the Researchers Do and Find?
• We identified two patients with triple-negative and basal-like breast cancer with avail-
able tissue from the primary breast cancer and multiple matched metastases, and per-
formed DNA whole genome sequencing and RNA sequencing on all tumors to identify
the genetic landscape of each tumor and define the genomic evolution of metastases
from the primary disease.
• We demonstrate that multiclonal seeding from the primary tumor to the metastases can
occur, indicating that metastatic cancers can originate from a collection of different
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subclones that together seed the metastatic site, rather than each metastasis forming
from a single cell.
• We also demonstrate that the majority of functionalmutations, those expressed and
likely to be drivingmetastasis, are established in the primary tumor rather than being
acquired during the spread of disease.
What Do These Findings Mean?
• This study demonstrates examples of multiclonal seeding of metastases frommultiple
cell populations in the original breast tumor of a patient with basal-like breast cancer.
• The high degree of similarity between the primary tumor and its metastases gives hope
that targetable drivers of metastasis are present in the primary tumor and, if effectively
treated, could prevent metastasis.
• A larger cohort of matched primaries with multiple sites of metastases per patient is
needed to understand the generalizability of these results and possible evolutionary dif-
ferences of metastasis across the different subtypes of breast cancer.
Introduction
Breast cancer patients who die from their disease typically succumb to metastatic disease rather
than to the primary tumor. Metastasis is a complex process likely involving many potentially
distinct mechanistic steps. Biologically similar tumors vary in their ability to seed distant meta-
static sites. Indeed, different molecular intrinsic subtypes of breast cancer as determined by the
PAM50 subtype classifier varymarkedly in their preferred sites for metastasis [1–3]. The lumi-
nal subtypes often metastasize to the bone, HER2-enriched tumors to the lung and liver, and
basal-like and claudin-low tumors to the brain, lung, and liver [1,2]. The metastatic process is
often described as a slow and continuous process of tumor evolution and acquisition of traits
such as increased genomic instability, motility, and the epithelial-to-mesenchymal transition.
Recent work in renal, prostate, ovarian, and lung cancer has identified significant amounts of
intratumor variability in the primary tumor, as well as identifying new driver mutations that
arose in metastases [4–8]. In several breast cancer analyses of targeted gene panels, there was
considerable concordance of mutations observedbetween primary tumors and matched metas-
tases [9–12]. This finding, combined with our increasing understanding that a particular
intrinsic subtype predicts the future site(s) of metastasis, suggests that in breast cancer at least
some of the metastatic potential already exists within the primary tumor [1–3,10]. To examine
this further, we studied the genomic relationship between the primary tumors and multiple
matched metastases of two patients with triple-negative breast cancer (TNBC), with both cases
also of the basal-like breast cancer intrinsic subtype.
A commonmeans of studying intratumor heterogeneity is to sample multiple parts of the
same tumor and then perform genetic or genomic assays on these different regions. A more
extreme approach to intratumor heterogeneity is to study a primary tumor and its associated
metastases to determine the extent to which the metastatic tumor genome was derived from
the primary tumor cells as opposed to being an independent tumor [5–7,13,14].Whether
metastases can develop from the primary tumor or require continued evolution and gain of
additional mutations in order to metastasize remains unknown in basal-like breast cancers,
and addressing this issue may have important implications for therapy. In order to study the
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genomic evolution of basal-like breast cancer, we performedDNA whole genome and mRNA
sequencing on two patients with matched primary tumors and multiple distant metastases.
Methods
Patient Consent and Tissue Processing
Tumor tissue was obtained frommetastatic breast cancer patients who consented to a rapid
autopsy at the University of North Carolina prior to death. Patient consent for the autopsy was
obtained in accordance with the UNCOffice for Human Research Ethics (OHRE) and criteria
established by the US Department of HHS, but this consent procedure was not IRB regulated.
There was no prospective analysis plan for this study. For Patient A7, a diagnostic skin punch
biopsy of the primary tumor was collected under protocol LCCC 9819 (NCT01000883) as a
fresh-frozen sample. For Patient A1’s primary, all metastatic tissues, and normal tissues from
both patients, collectionwas within 6 h of death for all metastatic sites identified prior to death
and at time of autopsy. Tissues were frozen in liquid nitrogen, and RNA and DNA were iso-
lated from each tissue using Qiagen RNAeasy and DNAeasy kits, respectively, according to
manufacturer protocol (Qiagen, Valencia, California) (S1 Table).
RNA-Seq
RNA was isolated with RNeasy Mini Kit (Qiagen), and sequencing libraries were prepared with
Illumina TruSeq RNA Sample Prep Kit (CAT #RS-122-2001) with the polyA select protocol,
except for the A7-Brain, which was first prepared using the Epicentre’s Ribo-Zero rRNA
Removal kit (Cat #RZH11042) [15]. RNA-seq was mapped with MapSplice [16] and quantified
with RSEM [17]. Upper-quantile normalized counts, log2 transformed, were combined with
the Cancer Genome Atlas (TCGA) breast RNA-seq data [18]. Samples were median centered
and clustered using the human breast cancer intrinsic gene set list [19], in Cluster 3.0 [20] and
visualizedwith Java TreeView v. 1.1.6r4 [21].
Illumina Library Construction and Whole Genome Sequencing
A previously describedprocedure was followed for library construction and sequencing [22].
Briefly, DNA was sheared (Covaris), end repaired (Lucigen), polyadenylated (Lucigen), and
ligated to adapters (Illumina) for paired-end data generation. DNA sequencing was performed
on the Illumina Genome Analyzer II and generated between 114 and 260 Gbp of sequence data
for each tissue studied and haploid coverage ranging from 29.24 to 72.17 (S2 Table).
Mutation Detection Pipeline
Reads were aligned to human reference build 36 (ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/
ARCHIVE/BUILD.36.3/special_requests/assembly_variants/; BWA 0.5.5, http://sourceforge.net/
projects/bio-bwa/),merged into a single binary alignment map (BAM) file, with duplicate reads
removed using Picard 1.07 (http://broadinstitute.github.io/picard/) by the established pipeline, as
previously reported [23]. To determine somatic variants, we utilized samtools [24] followed by
SomaticSniper using a somatic score40 and mapping quality40 [25,26]. Additional screen-
ing against dbSNP was used to remove probable germline variants [27,28]. Indels were identified
with Pindel [29] and GATK [30]. All variants were further annotated as previously described
[22,27] using VarScan2 [31] (parameters: –min-coverage = 30, –;min-var-freq = 0.08, –normal-
purity = 1, –p-value = 0.10, –somatic-p-value = 0.001, –validation = 1) to classify mutations as
reference, germline, somatic, or resulting from loss of heterozygosity (LOH). A Bayesian classifier
was applied to retain the somatic variants with a binomial log-likelihoodof at least 3 (parameters:
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 4 / 20
--llr-cutoff = 3, –tumor-purity = 0.95). False positives, as determined by strand specificity, consis-
tent positions near the ends of reads, and poorly mapped qualities were removed.
Mutations were assigned to four tiers: (1) coding, (2) conserved or regulatory, (3) unique
noncoding, and (4) repetitive noncoding regions.
Structural Variant Detection
Structural variants (SVs) were called with BreakDancer [32] and filtered using TIGRA_SV
[33]. Somatic copy number alterations were detected using CopyCat v1.6.9 (https://github.
com/chrisamiller/copycat), with 10,000 bp windows and default parameters.
Experimental Validation of Mutations
SNP arrays. Genotypes from Illumina Human OmniExpress BeadChip SNP arrays were
used to compare and confirm the heterozygous SNPs detected in the analyzedWGS data.
Small (1–2 bp) indels. Putative indels of 1–2 bp were converted to BED format and pro-
vided as target intervals for the GATK IndelRealigner [30,34]. The primary, metastases, and
matched normal breast tissue for each patient were then realigned to these BED files indepen-
dently. To validate the original predictions, we developed a matching algorithm that attempts
to match Varscan validation calls with the original indel predictions, as described [23]. All vali-
dated somatic indels were then manually reviewed using Integrative Genomics Viewer (IGV)
[35].
Medium (3–100 bp) indels. Indels of 3–100 bp were assembled using TIGRA [33] and
validated as previously described [23]. Variants that passed the strict validation were manually
reviewed.
Solid phase capture. Custom sequence capture validation was performedwith Roche
NimbleGen arrays for 97.3% of the Tier 1–3 somatic alterations and 68.6% of the SVs. Whole
genome amplified DNA was prepared for Illumina sequencing according to the manufacturer’s
protocol (Illumina, San Diego, California). DNA was fragmented with the Covaris S2 DNA
Sonicator (Covaris,Woburn, Massachusetts), adapter-ligated, SPRI-bead cleaned, and PCR
amplified. One μg of the 300–500 bp fragment library was hybridized to the NimbleGen HD2
probe set according to the manufacturer’s protocol (Nimblegen, Madison,Wisconsin). Follow-
ing hybridization, the library was PCR amplified for 16 cycles and quantified with the KAPA
SYBR FAST qPCR Kit (KAPA Biosystems,Woburn, Massachusetts) and diluted such that
180,000 clusters were sequenced per lane of the Illumina GAIIx.
Reads were mapped to the NCBI Build 36 referenceWUGSCVariant, which is a subset of
the NCBI36 sequences from Ensembl Release 46 (full assembly at ftp://ftp.ncbi.nih.gov/
genomes/H_sapiens/ARCHIVE/BUILD.36.3/special_requests/assembly_variants/).
The validation sequence was alignedwith BWA v0.5.9, and duplicate reads were marked
using Picard (v1.29). Updated versions of BWA and Picard were used for increased alignment
speed and variant detection efficiency. The RefCov package was used to evaluate the coverage
of target sequences (http://gmt.genome.wustl.edu/packages/refcov/).
Validation of SVs. Capture validation reads and mates were mapped to both the assem-
bled SV contigs and the reference with CrossMatch (version 1.080721). The threshold for an
acceptable alignment is1 mismatch at either end,1% substitutions, 1% indels, and a Cross-
Match score 50. An SV-supporting read is required to span the breakpoint on the SV contig,
align to 10 bases flanking on each side of the breakpoint, and have no alignment to the refer-
ence above the minimum alignment criteria. The somatic status of each SV was determined
using Fisher’s exact test between the matched tumor and normal sample. All validated calls
were manually reviewed.
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RNA Validation of Mutations
UNCeqR [36] was run on validationmode for all samples. In validation mode, the algorithm
accepts as input a set of predeterminedmutations, such as a list of mutations generated from
WGS/WES, and then looks within the RNA-seq data for expression evidence of the variants.
Tier 1 mutations were input into UNCeqR along with the RNA-seq BAM files alignedwith
MapSplice [16]. UNCeqR then calculated the number of reads of the reference and variant
alleles at each position interrogated. Mutations with less than 5 reads were considered as 0.
RNA variant allele fraction (VAF) was calculated as variant allele reads/total reads.
Clonality Analyses
The clonal structure of each tumor was inferred with SciClone (version 1.0.7) [37], with param-
eters minDepth = 75, copyNumberMargins = 0.25, and maximumClusters = 20. Single nucleo-
tide variants (SNVs) in copy number altered regions or with evidence of complete or partial
LOH were reviewed and excluded. Phylogeny was inferred using the clonevol R package
(https://github.com/hdng/clonevol) with default parameters.
Results
Case Histories
Patient A1 was a 65-y-old white woman who presented with stage IV TNBC and synchronous
metastases to the bone of the vertebral column (spinal), lung, adrenal gland, liver, and lymph
nodes. She was treated with radiation therapy to the breast, whole brain, and C3/T2 of the
spine, had one cycle of palliative paclitaxel without response, and died of disease 2-mo post-
diagnosis. Patient A7 was a 60-y-old African-Americanwoman diagnosedwith a 5-cm stage
IIIA TNBC. A pretreatment primary tumor biopsy was collected as a part of an existing tissue
collection protocol (LCCC 9819, NCT01000883), and she subsequently received neoadjuvant
doxorubicin plus cyclophosphamide followed by paclitaxel. She underwentmastectomy with
T2N2 residual disease, followed by adjuvant radiation therapy to the chest wall (SCV fossa and
axillary nodes). Patient A7 remained without evidence of disease recurrence for 17 mo before
presenting with metastases to the brain, kidney, liver, lung, and ribs. She received single-agent
capecitabine for 4 mo, with an initial minimal response and then progression both systemically
and in the central nervous system (CNS), followed by a single cycle of carboplatin that was dis-
continued because of poor tolerability and evidence of rapid progression. Patient A7 died of
disease 8 mo after her metastatic progression. For both patients, fresh frozen tissue was col-
lected at autopsy from primary tumor, distant metastases, and adjacent normal (nonmalignant
breast) tissue, except for the primary tumor specimen that was obtained before neoadjuvant
treatment was initiated in patient A7 (Fig 1).
Whole Genome Sequencing Coverage and Mutation
For the matched normal tissues, primary tumor (pretreatment biopsy for A7), and distant
metastases from patients A1 and A7, we performedDNA whole genome paired-end sequenc-
ing. For A7, we derived 138.38, 118.76, 260.93, 128.69, 204.34, 201.66, and 156.82 Gbp of
sequencing data from normal tissue, primary tumor, liver, lung, rib, kidney, and brain metasta-
ses, respectively, with corresponding haploid coverages ranging from 33.17X to 70.19X (S2
Table). For A1, we generated 265.53, 134.07, 115.85, 210.45, 114.31, and 131.03 Gbp of data
from normal tissue, primary tumor, liver, lung, adrenal, and spinal cord metastases, respec-
tively, with haploid coverage ranging from 30X to 72.16X (S2 Table).
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Candidate somatic changes were predicted using multiple algorithms. Confirmatory testing
of heterozygous mutations with genotype arrays confirmed biallelic detection of 80.47% to
89.63% in all samples (S2 Table). Candidate mutations were further validated with capture
probes corresponding to all putative somatic SNVs and small insertions/deletions (indels) that
overlap with coding exons, splice sites, and RNA genes (Tier 1), a number of high-confidence
SNVs and indels in noncoding conserved or regulatory regions (Tier 2), and nonrepetitive
regions of the human genome (Tier 3). In addition, we included predicted somatic SVs for vali-
dation. We obtained 40X haploid reference coverage for 87.48% to 94.02% of the targeted sites
(S3 Table). For A1, 73 Tier 1 point mutations, 1 Tier 1 indel, and 53 somatic SVs were con-
firmed across the primary tumor and metastases (S4–S6 Tables). For A7, there were 150 Tier 1
point mutations, 47 indels, and 40 SVs confirmed in the primary tumor and five metastatic
samples (S7–S9 Tables).
Genomic Relatedness of Primary Tumors and Metastases
Common gene expression patterns throughoutmetastasis. In order to study the degree
of relatedness between a primary tumor and its metastases, we performedmRNA-seq gene
expression analyses followed by hierarchical clustering analysis using a breast cancer “intrinsic”
gene list [19] including data from the 11 specimens studied here and 1,100 breast tumors from
the TCGA Project [18]. Regardless of physical or temporal distance between the primary and
its metastases, all tumors from these two patients clustered tightly together by patient (Fig 2).
By gene expression analysis using the PAM50 intrinsic breast cancer subtype predictor [19],
the primary tumors and metastases all maintained a basal-like subtype phenotype and clus-
tered with the basal-like samples from TCGA (Fig 2B); previous research has demonstrated a
high correlation among primaries and matched metastases by microarray gene expression
[1,38]. In patient A1, in whom the primary tumor and distant metastases were found synchro-
nously and who had limited exposure to chemotherapy and radiation prior to death, the gene
expression hierarchical cluster node correlation for the primary and the four metastases was
0.77 (Fig 2C). In patient A7, who received neoadjuvant chemotherapy and radiation and had a
17-mo interval separating the discovery of the primary tumor and distant metastases, the node
correlation for the six samples was 0.79 (Fig 2C). This demonstrates that subtype was
Fig 1. Clinical history and distribution of metastases from patients A1 and A7, who both had clinically triple-negative and basal-
like breast cancer.
doi:10.1371/journal.pmed.1002174.g001
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maintained throughout metastasis in these two patients and that, as we and others have shown
[1,38], distant metastases are typically much more similar to their original primary than they
are to other primary tumors or metastases from other patients.
Functional mutations are maintained and enriched during metastasis. We next studied
DNA-based data from each primary tumor and its multiple distant metastases. In patient A1,
54 genes were mutated with a VAF greater than 0.5% in the primary tumor (13 nonsilent muta-
tions were in the Catalogue of Somatic Mutations in Cancer [COSMIC] [39]) (S4 Table).
Almost every Tier 1 mutation present in the A1 primary tumor was identified in one or more
of the metastases (52/54), and in many cases the VAF was enriched in the metastasis (median:
5-fold enrichment, average: 8.8-fold, range: 1- to 38-fold; S4 Table, S1 Fig). Elevenmutated
genes were shared among the primary and all matched metastases:TARBP1, FCRL1,XIRP1,
TRMT1, PANX3,MYSM1, PHLDB3, TBC1D25,LOC284288,MDS2, and TP53. The adrenal
metastasis and spinal metastasis contained the most unique SNVs, with seven and nine, respec-
tively. The liver metastasis and lung metastasis did not have any private mutations at a
VAF > 1%, although the lung metastasis did share two mutations with the adrenal metastasis
that were not observed in the primary.
In patient A7, 75 Tier 1 genes were mutated with a VAF  0.4% in the primary tumor (14
of these nonsilent mutations were in COSMIC) (S7 Table, S1 Fig). The VAF in all of the metas-
tases had a median enrichment of 1.4-fold, closer to the primary tumor than in patient A1. All
of the mutations identified in the primary tumor were detected in at least one metastasis, and
65 mutations, including mutations in RUNX1T1, ADGRB2,KMT2C,RP1, TP53, and AKT3,
Fig 2. Molecular relatedness of matched primary and metastases. (A) Hierarchical clustering of patient A1 and A7’s tumors with 1,100
TCGA Primary samples and 98 normal breast samples analyzed using a breast cancer intrinsic gene list. The color bars under the
dendrogram indicate (i) where A1 (red) and A7 (blue) specimens are clustered and (ii) the PAM50 subtype of each sample (basal-like, red;
HER2-enriched, pink; luminal A, dark blue; luminal B, light blue; and normal-like, green). (B) The position of A1 (red) and the position of A7
(blue) within the basal-like cluster are highlighted. (C) The relationship of the primary and metastases for each patient based upon gene
expression patterns.
doi:10.1371/journal.pmed.1002174.g002
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were shared across the primary and all matched metastases. There were 75 mutations identified
in one or more of the metastases that were not observed in the primary tumor (8 of these non-
silent mutations also were in COSMIC). The majority of these metastasis-specificmutations
(54/75) were present in two or more metastases. Of the 21 mutations private to a single metas-
tasis, the liver and kidneymetastases had the most, with 7 and 8 private mutations, respectively.
The rib metastasis contained no unique mutations.
TP53 as a common driver of metastasis. TP53 alterations are frequently observed in
basal-like breast cancers [40]. TP53was the only shared somatic mutated gene between the two
patients and was present in every tumor specimen sequenced. Close examination of patient A1
data identified an 11 bp deletion in TP53 that was common to all samples (S2 Fig). In patient
A7, the TP53missensemutation H168R had a greater than 68% VAF in all tumors except the
brain metastasis (31%). While this exact mutation was not observed in the TCGA breast
cohort, a missensemutation was identified at the same position in one case (H168P) [41,42],
supporting the likelihood that alteration of TP53 is a founding event critical for the develop-
ment of basal-like breast cancer [43] and subsequent metastasis.
Mutations established early tend to be expressed and enriched in metastasis. We exam-
ined the mRNA expression data for evidence of expression of the somatic point mutations in
primary tumors and metastases. Interestingly, mutations shared between the primary and met-
astatic tumors were more likely to be expressed (Fig 3, black dots) and were expressed at higher
levels than mutations unique to metastasis (Fig 3, blue dots). In patient A1, 21/52 (40%) of the
mutations established in the primary were expressed in the metastases (Fig 3A, black dots). In
patient A7, 47/75 (63%) of the mutations established in the primary were expressed both in the
primary and in the metastases (Fig 3B, black dots).
Fewer mutations were detected only in the metastases, and those mutated transcripts had
lower RNA expression than mutations shared with the primary (Fig 3, blue dots). In patient
A1, 2 of the 3 mutations shared among more than one metastasis but not in the primary tumor
Fig 3. Gene expression of variant alleles. Variant allele fractions (VAFs) of each point mutation were determined from mRNA-
sequencing data and compared to those from combined whole genome sequencing (WGS) and validation sequencing data. Gene variants
shared in the primary and metastases (shared mutations, black), metastases but not primaries (metastases specific, blue), or only in one
metastasis (private, red) in patients A1 (A) and A7 (B) are shown.
doi:10.1371/journal.pmed.1002174.g003
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were expressed (Fig 3A, blue dots), while only 4 of the 18 private mutations (detected only in
individual metastases) were expressed (S4 Table, Fig 3A, red dots). In patient A7, 23/54 (43%)
of the mutations that were shared across the metastases but not with the primary tumor were
expressed, and 8/21 (38%) of the private mutations were expressed (S7 Table, Fig 3B).
Interestingly, many of the expressedmetastasis-specificmutations occur in genes that are
involved in DNA damage responses, RNA processing, and degradation of the extracellular
matrix (ECM). In patient A1, metastasis-specificmutations included FANCF and SMC6 (DNA
double-stranded break repair),DDX6 (promotes mRNA degradation), andHYAL3 (degrades
hyaluronan in the ECM) [44]. In patient A7, AQR, DOCK6, andHLTF were shared across
metastases and expressed. Metastasis-specificmutations in patient A7 included CASC3 (the
core of the exon junction complex), TIMP3 (degrades ECM), and LAMA5 (part of the ECM)
[44]. These could represent convergent evolutionary paths to the resistance of DNA damaging
agents and promotion of cell mobility and survival.
Structural variations tend to be established early in metastasis. To further explore the
development of larger genomic alterations during metastasis, Circos plots were generated to
illustrate the combined Tier 1 somatic mutations, DNA copy number alterations, and SVs for
each sequenced tumor (patient A1: S4–S6 Tables, S3 Fig; patient A7: S7–S9 Tables, S4 Fig).
These illustrate that, overall, SVs were mostly established in the primary tumor and maintained
through the different metastatic processes.
In patient A1, all 8 of the SVs in the primary tumor were shared with the metastases (S3
Fig), including one that was specifically shared with the adrenal and liver metastases (S6
Table). The metastases had few additional interchromosomal SVs, and these were shared,
except in the spinal metastasis. Interestingly, the spinal metastasis evolved to have many more
rearrangements between chromosomes 2 and either 3, 8, 12, or 16.
In patient A7, the brain and kidneymetastases shared most interchromosomal SVs with the
primary (S4 Fig, S9 Table). The rib and liver metastases had three private SV alterations each
(of a total of six and eight alterations, respectively), while the lung metastasis showed many
more private interchromosomal SVs than the other metastatic samples.
FBXW7-INPP4B fusion in patient A7. To confirm SVs, we created a modified genome
that represented the possible new alignments in RNA space. RealigningA7 data to this map
demonstrated expression of an FBXW7-RNF150 fusion gene observed in all A7 samples, indi-
cating early fusion of this gene in the development of this patient’s breast cancer (S5 Fig). Inter-
estingly, deletion of the last ten exons of FBXW7 was previously reported as a founding event
in a basal-like breast cancer [45]. The 50 end of the fusion in patient A7 began at exon 3 or 4 of
FBXW7, which likely inactivated FBXW7. The 30 end of the fusion occurred just before
RNF150, resulting in deletion of INPP4B. There was decreasedRNA expression of INPP4B in
this patient, further supporting the deletion of INPP4B by the FBXW7-RNF150 fusion gene
event. INPP4B has important implications in breast cancer that include DNA repair defects
[46], increased genomic instability [47], and inhibition of the PI3K pathway [48].
Multiclonal Evolution of Metastasis in Two Patients with TNBC
To understand the Darwinian evolution occurring in the primary tumor and throughout
metastasis [49], we established the subclonal relationships and phylogenetic trees for patient
A1 (Fig 4, S6–S8 Figs, S10 Table) and patient A7 (Fig 5, S9 and S10 Figs, S11 Table).
Subclonality analysis using Sciclone of the A1 patient samples demonstrates that the pri-
mary tumor predominantly contained clones 1, 3, 5, and 8, with very low allele fractions of
minor clones 2, 4, and 7 (S6 Fig, Fig 4A). Clone 1, established in the primary tumor, seeded all
other metastases. Of the other major clones in the primary, clones 3 and 5 seeded the lung
Tumor Evolution in Basal-like Breast Cancer
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Fig 4. Clonality analysis of each tumor from patient A1. VAFs among the primary and matched
metastases in patient A1 (A) and a representative evolutionary tree (B) colored by subclone based on the
clonality plots in panel A, with the width of the branch indicating the approximate percentage of that clone
within the tumor. Clone 1 is established in the primary tumor and seeded all distant metastases. Clones 2
and 4 from the primary tumor seeded the liver and the adrenal gland, with clone 7 concurrently seeding the
liver from the primary tumor. Clones 3 and 5 from the primary tumor seeded the lung, with clone 3 also
Tumor Evolution in Basal-like Breast Cancer
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metastasis, while clone 3 additionally seeded the spinal metastasis. This metastasis then contin-
ued to evolve, developing private clone 9 (Fig 4A, S6 Fig). These clones (3 and 5) were mutually
exclusive with minor clone 2, which was found in the primary tumor, lung, liver, and adrenal
metastases (S7 Fig). Two of the minor clones in the primary tumor (clones 2 and 4) became the
dominant clones in the liver and adrenal metastases, with additional private subclonal evolu-
tion in the adrenal metastasis (clone 6). Interestingly, clone 7 was established in the primary
tumor and also metastasized to the liver, but not to the adrenal, metastasis (Fig 4B). Using Clo-
nEvol, there were two potential models for clone 7 development that we were not able to fully
resolve; either it evolved (1) from clone 4 (S7A Fig) or (2) independently from clone 2 (S7B
and S8 Figs). This result demonstrates that the multiclonal metastatic potential residing in the
primary tumor is maintained throughmetastasis.
Importantly, patient A1 presented at stage IV and only received two doses of radiation and
one cycle of single-agent taxane before death. Thus, her primary-to-metastatic disease likely is
representative of the natural course of basal-like breast cancer rather than representing selec-
tion from the evolutionary pressure imposed by therapy.
In patient A7, the subclonal structure was determined by SciClone (S9 Fig, S11 Table), and a
single model of evolution was suggested by ClonEvol (S10 Fig). The primary tumor consisted
of one main clone (Fig 5A), seeding all other sites of metastasis at the highest VAF observed.
The main clone then diverged to two lineages, giving rise to clone 2 predominantly in the liver,
kidney, and rib and clone 4 predominantly in the lung and brain (Fig 5B). Clone 4 is present in
the lung and brain metastases at an almost equivalent VAF to the founding clone 1. Clones 2
and 6 in the rib are also present at an almost equivalent VAF to clone 1; clones 2 and 6 are seen
at a low VAF in the lung. These clonal data paint a complex picture with two possible explana-
tions: either the split of clone 1 into clones 2 and 6 and clone 4 occurred prior to metastatic
spread (Solution A, Fig 5B) or these clones cross seeded from the rib metastasis to the lung
metastasis (Solution B, Fig 5B). Clone 2 further evolved to clones 3 and 5 in the liver and kid-
ney metastases.We favor the first hypothesis, namely that clone 2 in the rib, liver, and kidney
metastases is at a VAF equivalent to the founding clone, indicating that the evolution of this
clone occurred before metastatic seeding.All metastases aside from the rib metastasis also con-
tained private subclones.
Discussion
Whole genome sequencing and mRNA sequencing of two TNBC/basal-likebreast cancer
patients with primary tumors and multiple matched metastases demonstrated significant
genetic similarity between the primary breast cancers and their matched metastases. Patient A1
demonstrated significant intratumoral heterogeneity established in the primary tumor and
multiclonal seeding of metastasis. Interestingly, patient A7 possibly contained a more homoge-
nous primary breast cancer that then led to diverse, heterogeneousmetastases. Even though
there is continued evolution, the acquisition of mutations private to a single metastasis likely
had limited impact on the metastatic potential, as these mutations were rarely expressed or
were expressed at low levels. In contrast to earlier findings in renal cell carcinoma of monoclo-
nal metastasis seeding [4], basal-like breast cancer metastases can be the result of multiclonal
seeding of cells established in the primary. The results presented here are inconsistent with a
single cell of a primary breast cancer seeding a distant metastasis [50]. Herein, we describe an
seeding the spine. Private clones include clone 6, specific to the adrenal metastasis; clone 8, specific to the
primary tumor; and clone 9, specific to the spinal metastasis.
doi:10.1371/journal.pmed.1002174.g004
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Fig 5. Clonality analysis of each tumor from patient A7. Clonality shared among the primary tumor and matched metastases in
patient A7 (A) and the representative evolutionary tree (B) colored by subclone identity based on the clonality plots in panel A, with the
width representative of the percentage of the clone within that tumor. Clone 1 was established in the primary tumor and maintained
through metastatic spread in every tumor. Clone 2 was present in the liver, kidney, and rib and at a low frequency in the lung, while
clones 3 and 5 were shared by the liver and kidney metastases. Clone 6 was present in the rib and a low frequency in the lung
metastases. Brain and lung metastases shared clone 4. Four metastases had a private clone not shared with any other tumor: clone 7
specific to the lung, clone 8 specific to the kidney, clone 9 specific to the liver, and clone 10 private to the brain.
doi:10.1371/journal.pmed.1002174.g005
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example of multiple subclones that resided within a primary tumor followed by multiclonal
seeding of all distant metastases as well as a common disruption of TP53.
In both patients, relatively fewmutations occurred once the tumor cells left the primary site,
and of those that did alter protein coding sequences, the mutations were not highly expressed
at the RNA level in general. The high correlation of gene expression among primaries and
matched metastases illustrates that subtype is typically maintained throughout metastasis [1],
and that specific intrinsic subtypes have an inherent tendency to metastasize to specific organs
[1,3]. Taken together, these results suggest that the metastatic potential was present within the
primary tumor of these two basal-like breast cancer patients. Here, we uncover a genetic expla-
nation for the close correlation of gene expression in metastases and matched primaries—
namely that, in the two cases examined, the samples from a given individual were much more
genetically similar than they were dissimilar, both on the DNA and RNA levels.
While the majority of genetic alterations present in metastases were shared with the
matched primary cancer in these two patients examined, we also identified a significant
amount of intratumoral heterogeneity, evident becausemultiple subclones were detected
within each metastasis. Patient A1 demonstrates that more than one subclone from the pri-
mary seeded each metastasis, and the intratumoral heterogeneity in the primary tumor setting
was mostly reflected in each metastasis. In patient A7, the lung metastasis exhibited diverse
intratumoral heterogeneity, with two small subclones (2 and 6) found at high frequency in
three of the other metastases. There are two possible explanations for the complex clonal pat-
terns seen in patient A7: either the two dominant clones (clones 2 and 4) were established in
the primary and were not sampled in the piece of the primary tumor that was actually
sequenced, or clones 2 and 6 in the rib cross seeded into the lung metastasis.While one metas-
tasis seeding another metastasis has been previously demonstrated in prostate cancer [7], we
also recognize that the A7 primary breast cancer likely had spatial heterogeneity that was not
fully captured by our sequencing [51]. In fact, the A7 primary breast cancer piece sequenced
was a skin punch biopsy taken from a 5 cm primary breast cancer, rather than a tumor resec-
tion. Hence, samples frommultiple portions of this tumor were not sequenced.Of the two pos-
sibilities, the most parsimonious explanation for the observations relevant to patient A7 is that
multiclonal seeding of the metastases did occur and that our limited sample did not permit
detection of clones 2 and 6. Hence, only subsequent deep sequencing of additional portions of
the A7 tumor would resolve the issue of monoclonal versus multiclonal seeding from the pri-
mary. Unfortunately, no additional specimens exist for this patient. Regardless of this, in
patient A7 multiple multiclonal seeding events were discovered, such as the rib metastasis seed-
ing the kidney and liver.
The genetic heterogeneity in both of the primary tumors and the resulting metastases may
explain why many metastatic TNBC patients fail to have a durable treatment response and
instead progress within a few years [52]. In particular, heterogeneity provides for a wealth of
individual genotypes, thus yielding a genetic diversity from which chemotherapy resistance
may arise. Treatment has been shown to select for therapy-resistant clones in primary breast
cancer [53–55], and therapy can select for subclones in the metastatic setting.
While our studies provided evidence of multiclonal seeding of metastasis in these two
patients, both with basal-like breast cancer, our results may or may not apply to a larger cohort
of patients with basal-like breast cancers, to other subtypes of breast cancers, or to other cancer
types. Even within the poor-prognosis basal-like subtype, patients often receive many more
lines of therapy and have more favorable responses to their therapies for a longer duration
than the two patients presented here. Furthermore, patients with luminal and HER2-enriched
breast cancer have comparatively more opportunities to benefit from targeted therapies such as
tamoxifen, aromatase inhibitors, and/or HER2 agonists such as trastuzumab, lapatinib, or
Tumor Evolution in Basal-like Breast Cancer
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pertuzumab. Since neither patient A1 nor A7 was treated with targeted therapies, there were
different selective pressures in the metastatic setting compared to current standard of care for
ER+ and HER2+ patients.
The basal-like subtype is a highly aggressive cancer that often metastasizes to the lung and
brain within 5 y of diagnosis. This is in contrast to luminal A breast cancers, which are typically
more indolent, are less likely to progress to stage IV, and typically metastasize first to the bone
[56]. The difference in these patterns of relapse and the timing with which they occur suggest
fundamental differences in disease progression between the subtypes [57] within the context of
drastically different treatment strategies. Continued analyses of larger datasets representing
each of the subtypes and patients with varying clinical histories will be necessary to identify
consistently altered genes to define early versus late drivers, metastasis-site specific alterations,
and differences among the mechanisms of metastasis across various subtypes of breast cancer.
Supporting Information
S1 Appendix. SupplementaryMaterials andMethods. In-depth description of the capture
array design, paired-end library preparation, and solid phase capture. Further description of
bioinformatic methods for clonality and determining significantlymutated genes.
(DOCX)
S1 Fig. Heat map of the DNA variant allele frequencyof Tier 1 mutations in patients A1
and A7. The vertical bar to the left of each heat map designates genes shared with the primary
and metastases (black), genes mutated in metastases but not in the primary (blue), and genes
private to a single individual metastasis (red) in (A) Patient A1 and (B) Patient A7.
(PDF)
S2 Fig. TP53Deletion in A1.Genome view of the 11 bp deletion of TP53 in Patient A1 at
chr17:7,579,474 to chr17:7,579,485, present in the primary tumor and all of the metastases.
(PDF)
S3 Fig. DNA alterations of matched primary and metastases of patient A7. (A–F): Circos
plot displays mutations, copy number, and structural rearrangements in the (A) primary, (B)
spinal, (C) lung, (D) liver, and (E) adrenal metastases. Translocations with significant read cov-
erage include shared (green) and private (red) interchromosomal and shared (purple) and pri-
vate (blue) intrachromosomal translocations.
(PDF)
S4 Fig. Circos plots of matched primary andmetastases of patient A7. (A–F): Circos plots
displaying mutations, copy number landscape, and structural rearrangements (order starting
from outside) in the (A) primary, (B) rib, (C) kidney, (D) liver, (E) brain, and (F) lung metasta-
ses. Translocations with significant read coverage include shared (green) and private (red)
interchromosomal and shared (purple) and private (blue) intrachromosomal translocations.
(PDF)
S5 Fig. FBXW7 fusion. Representative illustration of FBXW7 fusion and INPP4B deletion in
all tumors from A7.
(PDF)
S6 Fig. SciClone analysis of A1. SciClone analysis of variant allele frequencies in copy number
neutral regions of each tumor using Bayesian beta mixture modeling and multi dimensional
clustering of tumors from patient A1. Multiple clones are shared in the primary and metasta-
ses, with Clone 1 in the primary and all matched metastases; Clone 2: primary, adrenal, and
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 15 / 20
liver; Clone 3: primary, adrenal, and liver; Clone 4: primary, lung, and spine; Clone 5: primary,
adrenal, and liver; Clone 6: primary and lung; Clone 7: adrenal; Clone 8: primary and liver;
Clone 9: primary; and Clone 10: spinal.
(PDF)
S7 Fig. ClonEvol analysis of A1. ClonEvol demonstrates that Clones 1 and 2 are founding
clones that seed the distant metastases at different percentages. Clone 2 and Clone 3 are exclu-
sive of one another, leading to separate lineages. The proportion of each clone for each tumor
is demonstrated by the width of the nested shapes. Two possible models are presented.
(PDF)
S8 Fig. Representative evolutionary tree of an alternativemodel of A1. ClonEvol predicted
two possible evolutionary lineages of clones in patient A1. The first model is in Fig 5B. The
alternative model demonstrating that Clone 7 is independent of Clone 4 is presented.
(PDF)
S9 Fig. SciClone analysis of variant allele frequencies of patient A7. SciClone analysis of
only copy number neutral regions demonstrates multiclonal seeding of metastases. The Lung
metastasis contains both branches of the clonal tree, predominantly containing Clone 4 but
with a small fraction of Clone 2. In Contrast, the rib metastasis contains predominantly Clone
2 with a small minority of Clone 3. Private clones are seen in all metastases.
(PDF)
S10 Fig. Clonevol analysis of A7. ClonEvol of the copy number neutral mutations from Sci-
Clone analysis demonstrates one founding clone leading to a branched pattern of Clones 2 and
4. Private clones are present in all metastases.
(PDF)
S1 Table. Sample descriptions. Sample information for RNA and DNA sequencing runs,
including the name of matching fastQ files that have been uploaded to the Database of Geno-
types and Phenotypes (dbGAP) (accession number phs000676.v1.p1) as well as the clinical
information of Patients A1 and A7.
(XLSX)
S2 Table. Whole genome coverage. Includes coverage of input base pairs (Gb), haploid cover-
age, and concordance with heterozygous SNPs.
(XLS)
S3 Table. Capture validation. 40X, 30X, and 20X capture validation of whole genome
sequencing for all samples in patients A1 and A7.
(XLS)
S4 Table. Mutational landscapeof A1.Variant allele frequencies for variants in both DNA
and RNA. RNA samples with less than five reads were considered as having a VAF of 0 for
analysis purposes. The RNA VAF is the percent of reads at each loci with the variant in the
RNA sequencing identified from the DNA whole genome sequencing.
(XLSX)
S5 Table. DNA copy number alterations of A1.
(XLS)
S6 Table. Intrachromosomal and interchromosomal translocationsof tumors from patient
A1.
(XLS)
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 16 / 20
S7 Table. Mutation landscapeof A7. Variant allele frequencies for the mutation in both DNA
and RNA for each gene. RNA samples with less than five reads were considered as having a
VAF of 0 for analysis purposes. The RNA VAF is the percent of reads at each loci with the vari-
ant in the RNA sequencing identified from the DNA whole genome sequencing.
(XLSX)
S8 Table. DNA copy number alterations of A7.
(XLS)
S9 Table. Intrachromosomal and interchromosomal translocationsof tumors from patient
A7.
(XLSX)
S10 Table. Clonality analysis of A1. The table includes gene names, position, read depth,
DNA mutation, and cluster assignment for each mutation in copy number neural positions
used for clonality analysis.
(TXT)
S11 Table. Clonality analysis of A7. The table includes gene names, position, read depth,
DNA mutation, and cluster assignment for each mutation in copy number neutral positions
used for clonality analysis.
(TXT)
Acknowledgments
The authors thank the patients and their families, without whom this study would not have
been possible. The authors thankMei Huang of the UNC Tissue Pathology Facility and the
staff of the Office of Translational Research: Julie Benbow, Amy Garrett, and Amy Wheless.
We acknowledge the valuable contributions of current memberMichael D. McLellan and past
members of the McDonnell Genome Institute Nathan Dees and John Wallis, as well as the
graphic artistry of Josh McMichael and Jason Herschkowitz, who conceptualized and produced
some of the figures in this manuscript.
Author Contributions
Conceptualization:RKW LAC CMP ERM.
Data curation: JSP RTD RSF.
Formal analysis:KAHMBS KLK CAM LDWZMCWRSF.
Funding acquisition: LAC CMP ERM.
Investigation: XHWZ KAHMBS KLK CAM.
Methodology:RTD.
Resources: LAC.
Supervision:LD RKW LAC CMP ERM.
Validation: CAM.
Writing – original draft:KAHMBS KLK LDWZ XH JSP MCWRSF RTD RKW LAC CMP
ERM.
Writing – review& editing:KAHMBS KLK CAMCMP ERM.
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 17 / 20
References
1. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signa-
tures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012; 132: 523–35. doi: 10.
1007/s10549-011-1619-7 PMID: 21671017
2. Sihto H, Lundin J, Lundin M, Lehtima¨ki T, Ristima¨ki A, Holli K, et al. Breast cancer biological subtypes
and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
Breast Cancer Res BCR. 2011; 13: R87. doi: 10.1186/bcr2944 PMID: 21914172
3. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show pref-
erential site of relapse. Cancer Res. 2008; 68: 3108–3114. doi: 10.1158/0008-5472.CAN-07-5644
PMID: 18451135
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogene-
ity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883–892.
doi: 10.1056/NEJMoa1113205 PMID: 22397650
5. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized
lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346: 256–259. doi: 10.
1126/science.1256930 PMID: 25301631
6. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diver-
sity in genomic instability processes defines lung cancer evolution. Science. 2014; 346: 251–256. doi:
10.1126/science.1253462 PMID: 25301630
7. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolu-
tionary history of lethal metastatic prostate cancer. Nature. 2015; 520: 353–357. doi: 10.1038/
nature14347 PMID: 25830880
8. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and Temporal Het-
erogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLOS Med. 2015; 12:
e1001789. doi: 10.1371/journal.pmed.1001789 PMID: 25710373
9. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Charac-
terization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer
Discov. 2015; 5: 1164–1177. doi: 10.1158/2159-8290.CD-15-0369 PMID: 26410082
10. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pe´rez-Fidalgo JA, Wang Y, et al. Con-
cordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther.
2014; 13: 1382–1389. doi: 10.1158/1535-7163.MCT-13-0482 PMID: 24608573
11. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, et al. Metastatic progression
of breast cancer: insights from 50 years of autopsies. J Pathol. 2014; 232: 23–31. doi: 10.1002/path.
4288 PMID: 24122263
12. Moelans CB, van der Groep P, Hoefnagel LDC, van de Vijver MJ, Wesseling P, Wesseling J, et al.
Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of
breast cancer related genes. Cancer Lett. 2014; 344: 138–146. doi: 10.1016/j.canlet.2013.10.025
PMID: 24184827
13. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Mela-
noma from Precursor Lesions. N Engl J Med. 2015; 373: 1926–1936. doi: 10.1056/NEJMoa1502583
PMID: 26559571
14. McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, et al. Evolution of metastasis
revealed by mutational landscapes of chemically induced skin cancers. Nat Med. 2015; 21: 1514–
1520. doi: 10.1038/nm.3979 PMID: 26523969
15. Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A)
capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics.
2014; 15: 419. doi: 10.1186/1471-2164-15-419 PMID: 24888378
16. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, et al. MapSplice: accurate mapping of
RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010; 38: e178. doi: 10.1093/nar/
gkq622 PMID: 20802226
17. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a refer-
ence genome. BMC Bioinformatics. 2011; 12: 323. doi: 10.1186/1471-2105-12-323 PMID: 21816040
18. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular
Portraits of Invasive Lobular Breast Cancer. Cell. 2015; 163: 506–519. doi: 10.1016/j.cell.2015.09.033
PMID: 26451490
19. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of
breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: 1160–
1167. doi: 10.1200/JCO.2008.18.1370 PMID: 19204204
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 18 / 20
20. de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004; 20:
1453–1454. doi: 10.1093/bioinformatics/bth078 PMID: 14871861
21. Saldanha AJ. Java Treeview—extensible visualization of microarray data. Bioinformatics. 2004; 20:
3246–3248. doi: 10.1093/bioinformatics/bth349 PMID: 15180930
22. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by
sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058–1066. doi: 10.1056/
NEJMoa0903840 PMID: 19657110
23. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of
non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150: 1121–1134. doi: 10.1016/j.
cell.2012.08.024 PMID: 22980976
24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map for-
mat and SAMtools. Bioinforma Oxf Engl. 2009; 25: 2078–2079. doi: 10.1093/bioinformatics/btp352
PMID: 19505943
25. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification
of somatic point mutations in whole genome sequencing data. Bioinforma Oxf Engl. 2012; 28: 311–
317. doi: 10.1093/bioinformatics/btr665 PMID: 22155872
26. Larson DE, Abbott TE, Wilson RK. Using SomaticSniper to Detect Somatic Single Nucleotide Variants.
Curr Protoc Bioinforma Ed Board Andreas Baxevanis Al. 2014; 15: 15.5.1–15.5.8. doi: 10.1002/
0471250953.bi1505s45 PMID: 25431635
27. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically
normal acute myeloid leukaemia genome. Nature. 2008; 456: 66–72. doi: 10.1038/nature07485 PMID:
18987736
28. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database
of genetic variation. Nucleic Acids Res. 2001; 29: 308–311. PMID: 11125122
29. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points
of large deletions and medium sized insertions from paired-end short reads. Bioinforma Oxf Engl.
2009; 25: 2865–2871. doi: 10.1093/bioinformatics/btp394 PMID: 19561018
30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis
Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res.
2010; 20: 1297–1303. doi: 10.1101/gr.107524.110 PMID: 20644199
31. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and
copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22: 568–576.
doi: 10.1101/gr.129684.111 PMID: 22300766
32. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, et al. BreakDancer: an algorithm
for high-resolution mapping of genomic structural variation. Nat Methods. 2009; 6: 677–681. doi: 10.
1038/nmeth.1363 PMID: 19668202
33. Chen K, Chen L, Fan X, Wallis J, Ding L, Weinstock G. TIGRA: a targeted iterative graph routing
assembler for breakpoint assembly. Genome Res. 2014; 24: 310–317. doi: 10.1101/gr.162883.113
PMID: 24307552
34. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation
discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43: 491–
498. doi: 10.1038/ng.806 PMID: 21478889
35. Thorvaldsdo´ttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance
genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178–192. doi: 10.1093/bib/
bbs017 PMID: 22517427
36. Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, et al. Integrated RNA and DNA
sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 2014; 42: e107. doi:
10.1093/nar/gku489 PMID: 24970867
37. Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, et al. SciClone: inferring clonal archi-
tecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10:
e1003665. doi: 10.1371/journal.pcbi.1003665 PMID: 25102416
38. Bertucci F, Finetti P, Guille A, Ade´laïde J, Garnier S, Carbuccia N, et al. Comparative genomic analysis
of primary tumors and metastases in breast cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.8349
PMID: 27028851
39. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the
world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43: D805–D811.
doi: 10.1093/nar/gku1075 PMID: 25355519
40. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;
490: 61–70. doi: 10.1038/nature11412 PMID: 23000897
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 19 / 20
41. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics por-
tal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:
401–404. doi: 10.1158/2159-8290.CD-12-0095 PMID: 22588877
42. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex
cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1. doi: 10.1126/
scisignal.2004088 PMID: 23550210
43. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spec-
trum of primary triple-negative breast cancers. Nature. 2012; 486: 395–399. doi: 10.1038/nature10933
PMID: 22495314
44. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information about genes,
proteins and diseases. Trends Genet TIG. 1997; 13: 163. PMID: 9097728
45. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast
cancer metastasis and xenograft. Nature. 2010; 464: 999–1005. doi: 10.1038/nature08989 PMID:
20393555
46. Ip LRH, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, et al. Loss of INPP4B causes a
DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor
treatment. Oncotarget. 2015; 6: 10548–10562. doi: 10.18632/oncotarget.3307 PMID: 25868852
47. Weigman VJ, Chao H-H, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like Breast cancer
DNA copy number losses identify genes involved in genomic instability, response to therapy, and
patient survival. Breast Cancer Res Treat. 2012; 133: 865–880. doi: 10.1007/s10549-011-1846-y
PMID: 22048815
48. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evi-
dence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K sig-
naling. Cancer Cell. 2009; 16: 115–125. doi: 10.1016/j.ccr.2009.06.006 PMID: 19647222
49. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phyloge-
netic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A. 2008; 105:
13081–13086. doi: 10.1073/pnas.0801523105 PMID: 18723673
50. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by sin-
gle-cell sequencing. Nature. 2011; 472: 90–94. doi: 10.1038/nature09807 PMID: 21399628
51. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversifica-
tion of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015; 21: 751–759. doi:
10.1038/nm.3886 PMID: 26099045
52. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncol Williston Park.
2008; 22: 1233–1239. PMID: 18980022
53. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-Therapy-Resistant ESR1 Variants
Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Rep. 2013;4. doi:
10.1016/j.celrep.2013.08.022 PMID: 24055055
54. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clini-
cal resistance to a PI(3)Kα inhibitor. Nature. 2015; 518: 240–244. doi: 10.1038/nature13948 PMID:
25409150
55. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, et al. Aromatase inhibition remodels the clonal
architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016; 7: 12498. doi: 10.1038/
ncomms12498 PMID: 27502118
56. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of Breast Cancer Subtypes
and Treatment on Survival: An Analysis Spanning Two Decades. Cancer Epidemiol Biomarkers Prev.
2012; 21: 1848–1855. doi: 10.1158/1055-9965.EPI-12-0474 PMID: 22989461
57. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast
cancer response to aromatase inhibition. Nature. 2012; 486: 353–360. doi: 10.1038/nature11143
PMID: 22722193
Tumor Evolution in Basal-like Breast Cancer
PLOS Medicine | DOI:10.1371/journal.pmed.1002174 December 6, 2016 20 / 20
